Cannabis Stocks Crash /Tilray: Boom And Bust
Tilray is one of the cannabis companies that saw its shares rise massively prior to legalization in Canada, but shares have gone down a lot since then.
Tilray (TLRY) is based in the Vancouver Island town of Nanaimo, Canada, where the company is responsible for
"cultivating and delivering the benefits of medical cannabis safely and reliably," according to its website.
As with much of the marijuana industry, Tilray is losing money as it tries to expand in Canada and globally.
The company has a presence, of some kind, in at least 12 countries. But it has lost money over the past six quarters.
Tilray (TLRY) reported 2019 Q3 results that were mixed with strong medical sales and struggling recreational sales in Canada.
The company sold more than double the amount of cannabis it did last quarter but average pricing also dropped 30%.
More importantly, the company's weaker balance sheet will become its biggest near-term impediment to growth.
Disclaimer:
We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature,
and are therefore are unqualified to give investment recommendations.
Always do your own research and consult with a licensed investment professional before investing.
This communication is never to be used as the basis of making investment decisions, and it is for entertainment purposes only.
Tilray (TLRY) is based in the Vancouver Island town of Nanaimo, Canada, where the company is responsible for
"cultivating and delivering the benefits of medical cannabis safely and reliably," according to its website.
As with much of the marijuana industry, Tilray is losing money as it tries to expand in Canada and globally.
The company has a presence, of some kind, in at least 12 countries. But it has lost money over the past six quarters.
Tilray (TLRY) reported 2019 Q3 results that were mixed with strong medical sales and struggling recreational sales in Canada.
The company sold more than double the amount of cannabis it did last quarter but average pricing also dropped 30%.
More importantly, the company's weaker balance sheet will become its biggest near-term impediment to growth.
Disclaimer:
We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature,
and are therefore are unqualified to give investment recommendations.
Always do your own research and consult with a licensed investment professional before investing.
This communication is never to be used as the basis of making investment decisions, and it is for entertainment purposes only.
코멘트:
